US5098904A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Cerebral function enhancing pyrimidinyl derivatives
Assignee: Bristol Myers Squibb Co
•
Filing: 1990-06-27
•
Granted: 1992-03-24
•
Expires: 2010-06-27
Abstract
Abstract A series of pyprimidinyl compounds of formulae I, II and III; ##STR1## wherein R 1 and R 2 are independently selected from hydrogen and hydroxy; R 3 is selected from hydrogen, hydroxy, or oxo, with the proviso that R 3 can only be oxo when R 1 and R 2 are hydrogen, and further that R 1 , R 2 , and R 3 cannot all be hydrogen or hydroxy at the same time; and the solid and dotted lines refer to either a double covalent bond or a single covalent bond with another hydrogen atom covalently bonded to the carbon terminus end. The compounds of this invention possess cognition and memory enhancing activity.
Inventors
- 👤 Ronald J. Mattson
- 👤 Robert Mayol
- 👤 Michael E. Brady
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-10 01:48
CPC Classifications
C; C07; C07D; C07D401/00; C07D401/14; A; A61; A61P; A61P25/00; A61P25/28
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
51 words
The compound of formula I ##STR34## and its pharmaceutically acceptable salts thereof, wherein R 1 , R 2 and R 3 are independently selected from hydrogen and hydroxy with the proviso that R 1 , R 2 , and R 3 cannot all be hydrogen or hydroxy at the same time.
Claim 2
Dependent Claim
51 words
The compound of formula I ##STR34## and its pharmaceutically acceptable salts thereof, wherein R 1 , R 2 and R 3 are independently selected from hydrogen and hydroxy with the proviso that R 1 , R 2 , and R 3 cannot all be hydrogen or hydroxy at the same time.
Claim 3
Dependent Claim
12 words
A compound of Formula II and its pharmaceutically acceptable salts thereof ##STR35##
Claim 4
Dependent Claim
12 words
A compound of Formula II and its pharmaceutically acceptable salts thereof ##STR35##
Claim 5
Dependent Claim
12 words
A compound of Formula III and its pharmaceutically acceptable salts thereof ##STR36##
Claim 6
Dependent Claim
12 words
A compound of Formula III and its pharmaceutically acceptable salts thereof ##STR36##
Claim 7
Dependent Claim
6 words
The compound of claim 1, 3-hydroxy-1-[[1-[2-(trifluoromethyl)-4-pyrimidinyl]-4-piperidinyl]methyl]-2-pyrrolidinone.
Claim 8
Dependent Claim
6 words
The compound of claim 1, 4-hydroxy-1-[[1-[2-(trifluoromethyl)-4-pyrimidinyl]-4-piperidinyl]methyl]-2-pyrrolidinone.
Claim 9
Dependent Claim
6 words
The compound of claim 1, 5-hydroxy-1-[[1-[2-(trifluoromethyl)-4-pyrimidinyl]-4-piperidinyl]methyl]-2-pyrrolidinone.
Claim 10
Dependent Claim
6 words
The compound of claim 1, 3,4-dihydroxy-1-[[1-[2-(trifluoromethyl)-4-pyrimidinyl]-4-piperidinyl]methyl]-2-pyrrolidinone.
Claim 11
Dependent Claim
6 words
The compound of claim 1, 3,5-dihydroxy-1-[[1-[2-(trifluoromethyl)-4-pyrimidinyl]-4-piperidinyl]methyl]-2-pyrrolidinone.
Claim 12
Dependent Claim
6 words
The compound of claim 1, 4,5-dihydroxy-1-[[1-[2-(trifluoromethyl)-4-pyrimidinyl]-4-piperidinyl]methyl]-2-pyrrolidinone.
Claim 13
Dependent Claim
33 words
A method for enhancing cognition and memory in a mammal in need of such treatment which comprises systemic administration to the mammal of an effective dose of a compound claimed in claim 1.
Claim 14
Dependent Claim
32 words
A pharmaceutical composition in dosage unit form suitable for systemic administration to a mammalian host comprising a pharmaceutical carrier and cognition and memory enhancing amount of a compound claimed in claim 1.
Claim 15
Dependent Claim
33 words
A method for enhancing cognition and memory in a mammal in need of such treatment which comprises systemic administration to the mammal of an effective dose of the compound claimed in claim 2.
Claim 16
Dependent Claim
32 words
A pharmaceutical composition in dosage unit form suitable for systemic administration to a mammalian host comprising a pharmaceutical carrier and cognition and memory enhancing amount of the compound claimed in claim 2.
Claim 17
Dependent Claim
33 words
A method for enhancing cognition and memory in a mammal in need of such treatment which comprises systemic administration to the mammal of an effective dose of the compound claimed in claim 3.
Claim 18
Dependent Claim
32 words
A pharmaceutical composition in dosage unit form suitable for systemic administration to a mammalian host comprising a pharmaceutical carrier and cognition and memory enhancing amount of the compound claimed in claim 3.
References Cited (Backward Citations)
US3398151A
Cited
US3558777A
Cited
US3717634A
Cited
US3907801A
Cited
US3976776A
Cited
GB2023594A
Cited
US4411901A
Cited
US4361565A
Cited
US4423049A
Cited
US4524206A
Cited
US4668687A
Cited
US4826843A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-03-24 | 1995-09-23 | 1996-03-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-03-24 | 1999-09-23 | 2000-03-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-03-24 | 2003-09-23 | 2004-03-24 | $7700.00 | Window Closed / Lapsed |